TPX-0131
- Generic Name
- TPX-0131
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
Phase 1
Terminated
- Conditions
- Non Small Cell Lung CancerNon-Small Cell Lung CancerNSCLCAdvanced Solid TumorMetastatic Solid TumorALK Gene Mutation
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04849273
- Locations
- 🇺🇸
Local Institution - 2103, Hackensack, New Jersey, United States
🇺🇸Local Institution - 2102, Fairfax, Virginia, United States
🇰🇷Local Institution - 6304, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath